Your browser doesn't support javascript.
loading
Flibanserin for Treating Hypoactive Sexual Desire Disorder
Journal of Menopausal Medicine ; : 9-13, 2016.
Artículo en Inglés | WPRIM | ID: wpr-10693
ABSTRACT
There have been several products developed for male sexual dysfunction. However, developing agents for female sexual dysfunction is lagging behind for various reasons. Sildenafil citrate (Viagra) and Tadalafil (Cialis), which have been prescribed for male sexual function disorders, are known to act on vessels.[1] On the other hand, flibanserin is thought to act on brain. Flibanserin has been approved by U. S. Food and Drug Administration (FDA) for treatment of hypoactive sexual desire disorder (HSDD) of premenopausal women in 2015, and is expected to be released in South Korea soon. Authors wrote this article to acknowledge flibanserin to sexologists for females or physicians for menopausal medicine, so that this agent can be safely used for females who have HSDD.
Asunto(s)

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Conducta Sexual / United States Food and Drug Administration / Encéfalo / Ácido Cítrico / Disfunciones Sexuales Psicológicas / Citrato de Sildenafil / Tadalafilo / Mano / Corea (Geográfico) Límite: Femenino / Humanos / Masculino País/Región como asunto: Asia Idioma: Inglés Revista: Journal of Menopausal Medicine Año: 2016 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Conducta Sexual / United States Food and Drug Administration / Encéfalo / Ácido Cítrico / Disfunciones Sexuales Psicológicas / Citrato de Sildenafil / Tadalafilo / Mano / Corea (Geográfico) Límite: Femenino / Humanos / Masculino País/Región como asunto: Asia Idioma: Inglés Revista: Journal of Menopausal Medicine Año: 2016 Tipo del documento: Artículo